Hormone therapy, mammographic density, and breast cancer risk

Maturitas

Volumn 64, Issue 1, 2009, Pages 20-26

  Martin, Lisa J ^a   Minkin, Salomon ^a   Boyd, Norman F ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Breast cancer; Hormone therapy; Mammographic density

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; NORETHISTERONE ACETATE; PLACEBO; PROGESTERONE; RALOXIFENE; TAMOXIFEN; TESTOSTERONE; TIBOLONE;

AGE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CAUSAL ATTRIBUTION; CLINICAL TRIAL; ESTRADIOL BLOOD LEVEL; HORMONAL THERAPY; HUMAN; MAMMOGRAPHY; MENOPAUSE; PARITY; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BREAST; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MAMMOGRAPHY; RISK FACTORS; TAMOXIFEN;

EID: 69349084300     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.07.009     Document Type: Review

References (73)

1. Byrne C., Schairer C., Wolfe J., et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 87 (1995) 1622-1629
2. Boyd N.F., Guo H., Martin L.J., et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 356 (2007) 227-236
3. Schatzkin A., and Gail M. The promise and peril of surrogate end points in cancer research. Nat Rev 2 (2002) 19-27
4. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8 (1988) 431-440
5. Freedman L.S., Graubard B.I., and Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11 (1992) 167-178
6. Wolfe J.N. Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 37 (1976) 2486-2492
7. Wolfe J.N. Breast patterns as an index of risk for developing breast cancer. Am J Roentgenol 126 (1976) 1130-1137
8. McCormack V.A., and dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15 (2006) 1159-1169
9. Ursin G., Wu A.H., Bernstein L., et al. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 12 (2003) 332-338
10. Martin L.J., and Boyd N. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 10 (2008) 1-14
11. Boyd N.F., Lockwood G.A., Byng J., Tritchler D.L., and Yaffe M. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7 (1998) 1133-1144
12. Li T., Sun L., Miller N., et al. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 343-349
13. Vachon C.M., Kuni C.C., and Anderson K. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control 11 (2000) 653-662
14. Kelsey J.L., Gammon M.D., and John E.S. Reproductive factors and breast cancer. Epidemiol Rev 15 (1993) 36-47
15. Noh J.J., Maskarinec G., Pagano I., Cheung L.W., and Stanczyk F.Z. Mammographic densities and circulating hormones: a cross-sectional study in premenopausal women. Breast 15 (2006) 20-28
16. Tamimi R.M., Hankinson S.E., Colditz G.A., and Byrne C. Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomarkers Prev 14 (2005) 2641-2647
17. Aiello E.J., Tworoger S.S., Yasui Y., et al. Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women. Cancer Epidemiol Biomarkers Prev 14 (2005) 1411-1417
18. Warren R., Skinner J., Sala E., et al. Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women. Cancer Epidemiol Biomarkers Prev 15 (2006) 1502-1508
19. Boyd N.F., Stone J., Martin L.J., et al. The association of breast mitogens with mammographic densities. Br J Cancer 87 (2002) 876-882
20. Verheus M., Peeters P.H.M., van Noord P.A.H., van der Schouw Y.T., Grobbee D.E., and van Gils C.H. No relationship between circulating levels of sex steroids and mammographic breast density: the Prospect-EPIC cohort. Breast Cancer Res 9 (2007) R53
21. Bremnes Y., Ursin G., Bjurstam N., Rinaldi S., Kaaks R., and Gram I.T. Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women. Int J Cancer 121 (2007) 2506-2511
22. Greendale G.A., Palla S.L., Ursin G., et al. The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Am J Epidemiol 162 (2005) 826-834
23. Johansson H., Gandini S., Bonanni B., et al. Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women. Breast Cancer Res Treat 108 (2008) 57-67
24. Tamimi R.M., Byrne C., Colditz G.A., and Hankinson S.E. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 99 (2007) 1178-1187
25. Boyd N.F., Martin L.J., Chavez S., et al. Mammographic density and breast tissue composition in young women. Lancet Oncol 10 (2009) 569-580
26. Byrne C., Colditz G.A., Pollak M., Willet W.C., Speizer F.E., and Hankinson S.E. Plasma insulin-like growth factor-I, insulin-like growth factor binding protein-3 and mammographic density. Cancer Res 60 (2000) 3744-3748
27. Diorio C., Pollak M., Byrne C., et al. Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14 (2005) 1065-1073
28. Maskarinec G., Williams A.E., and Kaaks R. A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer 107 (2003) 991-996
29. dos Santos Silva I., Johnson N., De Stavola B., et al. The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women. Cancer Epidemiol Biomarkers Prev 15 (2006) 449-455
30. Bremnes Y., Ursin G., Bjurstam N., Rinaldi S., Kaaks R., and Gram I.T. Insulin-like growth factor and mammographic density in postmenopausal Norwegian women. Cancer Epidemiol Biomarkers Prev 16 (2007) 57-62
31. Guo Y.P., Martin L.J., Hanna W., et al. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 10 (2001) 243-248
32. Valko M., Izakovic M., Mazur M., Rhodes C.J., and Talser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 266 (2004) 37-56
33. Mukai F.H., and Goldstein B.D. Mutagenicity of malondialdehyde, a decomposition product of peroxidized polyunsaturated fatty acids. Science 191 (1976) 868-869
34. Basu A.K., and Marnett L.J. Unequivocal demonstration that malondialdehyde is a mutagen. Carcinogenesis 4 (1983) 331-333
35. Kadiiska M.B., Gladen B.C., Baird D.D., et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning. Free Radic Biol Med 38 (2005) 698-710
36. Boyd N.F., and McGuire V. Evidence of lipid peroxidation in premenopausal women with mammographic dysplasia. Cancer Lett 50 (1990) 31-37
37. Boyd N.F., Connelly P., Byng J., et al. Plasma lipids, lipoproteins, and mammographic densities. Cancer Epidemiol Biomarkers Prev 4 (1995) 727-733
38. Hong C.C., Tang B.K., Rao V., et al. Cytochrome P450 1A2 (CYP1A2) activity, mammographic density, and oxidative stress: a cross-sectional study. Breast Cancer Res 6 (2004) R338-R351
39. Leygue E., Snell L., Dotzlaw H., et al. Lumican and decorin are differentially expressed in human breast carcinoma. J Pathol 192 (2009) 313-320
40. Alowami S., Troup S., Al-Haddad S., Kirkpatrick I., and Watson P.H. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 5 (2003) R129-R135
41. Pike M.C., Pearce C.L., and Wu A.H. Prevention of cancers of the breast, endometrium and ovary. Oncogene 23 (2004) 6379-6391
42. Rosner B., and Colditz G.A. Nurses' health study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst 88 (1996) 359-364
43. Wolfe J.N. Breast parenchymal patterns and their changes with age. Radiology 121 (1976) 545-552
44. Grove J.S., Goodman M.J., Gilbert F.I., and Clyde D. Factors associated with breast structures in breast cancer patients. Cancer 43 (1979) 1895-1899
45. Boyd N., Martin L., Stone J., Little L., Minkin S., and Yaffe M. A longitudinal study of the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev 11 (2002) 1048-1053
46. Ziv E., Shepherd J., Smith-Bindman R., and Kerlikowske K. Mammographic breast density and family history of breast cancer. J Natl Cancer Inst 95 (2005) 556-558
47. Brisson J., Morrison A.S., and Kopans D.B. Height and weight, mammographic features of breast tissue, and breast cancer risk. Am J Epidemiol 119 (1984) 371-381
48. Grove J.S., Goodman M.J., Gilbert F., and Mi M.P. Factors associated with mammographic pattern. Br J Radiol 58 (1985) 21-25
49. Boyd N.F., Martin L.J., Sun L., et al. Body size, mammographic density and breast cancer risk. Cancer Epidemiol Biomarkers Prev 15 (2006) 2086-2092
50. Key T.J., Appleby P.N., Reeves G.K., et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95 (2003) 1218-1226
51. Sellers T.A., Vachon C.M., Pankratz V.S., et al. Association of childhood and adolescent anthropometric factors, physical activity, and diet with adult mammographic breast density. Am J Epidemiol 166 (2007) 456-464
52. Lawlor D.A., Okasha M., Gunnell D., Smith G.D., and Ebrahim S. Associations of adult measures of childhood growth with breast cancer: findings from the British Women's Heart and Health Study. Br J Cancer 89 (2003) 81-87
53. Hunter D.J., and Willett W.C. Diet, body size, and breast cancer. Epidemiol Rev 15 (1993) 110-132
54. Ekbom A. Growing evidence that several human cancers may originate in utero. Semin Cancer Biol 8 (1998) 237-244
55. Ekbom A., Thurfjell E., Hsieh C.C., Trichopoulos D., and Adami H.O. Perinatal characteristics and adult mammographic patterns. Int J Cancer 61 (1995) 177-180
56. Boyd N.F., Dite G.S., Stone J., et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 347 (2002) 886-894
57. Chlebowski R.T., Hendrix S.L., Langer R., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial. J Am Med Assoc 289 (2003) 3243-3253
58. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90 (1998) 1371-1388
59. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. J Am Med Assoc 295 (2006) 2727-2741
60. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxfen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
61. Freedman M., San Martin J., O'Gorman J., et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 93 (2001) 51-56
62. Greendale G.A., Reboussin B.A., Slone S., Wasilauskas C., Pike M.C., and Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 95 (2003) 30-37
63. McTiernan A., Martin D.F., Peck J.D., et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative Randomized Trial. J Natl Cancer Inst 97 (2005) 1366-1376
64. Hofling M., Lundstrom E., Azavedo E., Svane G., Hirschberg A.L., and von Schoultz B. Testosterone addition during menopausal hormone therapy: effects on mammographic breast density. Climacteric 10 2 (2007) 155-163
65. Eilertsen A.L., Karssemeijer N., Skaan P., Qvigstad E., and Sandset P.M. Differential impact of converntional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. Menopause 115 (2008) 773-779
66. Lundstrom E., Wilczek B., von Palffy Z., Soderqvist G., and von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 181 (1999) 348-352
67. Vachon C.M., Sellers T.A., Vierkant R.A., Wu F.F., and Brandt K.R. Case-control study of increased mammographic breast density response to hormone replacement therapy. Cancer Epidemiol Biomarkers Prev 11 (2002) 1382-1388
68. Boyd N.F., Martin L.J., Li Q., et al. Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15 (2006) 961-966
69. Vachon C.M., Ingle J.N., Suman V.J., et al. Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen. Breast 16 (2007) 204-210
70. Cuzick J., Warwick J., Pinney E., Warren R.M.L., and Duffy S.W. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96 (2004) 621-628
71. Brisson J., Brisson B., Coté G., Maunsell E., Bérubé S., and Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 9 (2000) 911-915
72. Cuzick J, Warwick J, Pinney L, et al. Change in breast density as a biomarker of breast cancer risk reduction. Abstract No. 61, presented at the San Antonio breast cancer symposium; 2008.
73. Becker S., and Kaaks R. Exogenous and endogenous hormones, mammographic density and breast cancer risk: can mammographic density be considered an intermediate marker of risk?. Recent Results Cancer Res 181 (2009) 135-157